ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of ...

The "In Situ Hybridization Market Report by Product, Technique, Application, End User, Countries and Company Analysis ...

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, developed ...

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of Applied Chemistry ...

Some tumours are cancerous, but not all cancers can form tumours. How are cancers different from the abnormal pumps you ...

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new ...

January 12, 2026. Infinitusbio.AI, a U.S.-based Pharmatech company and creator of the proprietary Simulative AI Digital Cell Clone platform, and Oncovita, a Paris-based biotechnology company spun out ...

In this phase 3 trial, researchers aimed to study the efficacy of tumor bed boost and moderately hypofractionated whole breast irradiation in patients with non-low-risk DCIS.